Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Second-line Treatment”

1,284 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,284 results

Testing effectiveness (Phase 2)Looking for participantsNCT06242067
What this trial is testing

Second-line Treatment of Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Qilu Hospital of Shandong University 50
Large-scale testing (Phase 3)Ended earlyNCT01006252
What this trial is testing

Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Who this might be right for
Melanoma
Eli Lilly and Company 336
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07022301
What this trial is testing

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Who this might be right for
Small Cell Lung Cancer Extensive StageResistance to Immunotherapy
First Affiliated Hospital of Wannan Medical College 25
Testing effectiveness (Phase 2)UnknownNCT05447715
What this trial is testing

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Weijian Guo 134
Large-scale testing (Phase 3)Study completedNCT01767155
What this trial is testing

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Who this might be right for
Endometrial Cancer
AEterna Zentaris 511
Testing effectiveness (Phase 2)WithdrawnNCT03818997
What this trial is testing

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Who this might be right for
Esophageal CancerBiliary Tract CancerGastroEsophageal Cancer+1 more
European Organisation for Research and Treatment of Cancer - EORTC
Large-scale testing (Phase 3)Active Not RecruitingNCT04833114
What this trial is testing

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
GWT-TUD GmbH 306
Large-scale testing (Phase 3)UnknownNCT01630733
What this trial is testing

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Achieve Life Sciences 700
Large-scale testing (Phase 3)Study completedNCT00478049
What this trial is testing

Iressa as Second Line Therapy in Advanced NSCLC-Asia

Who this might be right for
NSCLC
AstraZeneca 163
Not applicableLooking for participantsNCT06751953
What this trial is testing

Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment

Who this might be right for
Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University 10
Large-scale testing (Phase 3)Looking for participantsNCT06497985
What this trial is testing

Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
Chipscreen Biosciences, Ltd. 430
Testing effectiveness (Phase 2)Study completedNCT02945852
What this trial is testing

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Who this might be right for
Small Cell Lung Cancer
Fan Yun, MD 40
Early research (Phase 1)Not Yet RecruitingNCT06822985
What this trial is testing

QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Who this might be right for
HCC - Hepatocellular Carcinoma
Wan-Guang Zhang 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06783348
What this trial is testing

Radiopharmaceutical Treatment of Advanced Kidney Cancer

Who this might be right for
Metastatic Clear Cell Renal Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC 48
Testing effectiveness (Phase 2)Study completedNCT00061308
What this trial is testing

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Who this might be right for
Peritoneal CancerOvarian CancerNeoplasms, Ovarian+1 more
GlaxoSmithKline 75
Large-scale testing (Phase 3)Study completedNCT02227238
What this trial is testing

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

Who this might be right for
HIV Infections
ViiV Healthcare 627
Testing effectiveness (Phase 2)UnknownNCT01092585
What this trial is testing

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Who this might be right for
Melanoma
Genta Incorporated 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06304025
What this trial is testing

Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment

Who this might be right for
Graft Versus Host Disease
Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle 10
Testing effectiveness (Phase 2)Study completedNCT00637091
What this trial is testing

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Who this might be right for
Advanced Colorectal Cancer
Asan Medical Center 40
Testing effectiveness (Phase 2)UnknownNCT02134990
What this trial is testing

Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Oshadi Drug Administration 20
Load More Results